Christopher Viehbacher

Chris Viehbacher is the Managing Partner of Gurnet Point Capital. Gurnet Point is a Boston based investment fund associated with the Bertarelli family and has a $2 billion capital allocation. Viehbacher is a Board member of Axcella Health, BEFORE Brands, Crossover Health and PureTech Health plc. He is also Chairman of Boston Pharmaceuticals, a Gurnet Point portfolio company and Vedanta, a PureTech portfolio company as well as Vice Chairman for Nuvelution Pharmaceuticals. He is also a member of The Board of Trustees of Northeastern University. Viehbacher is the former CEO and Member of the Board of Directors of Sanofi, a Fortune 50 Biopharmaceutical company based in Paris. He was also the Chairman of the Board of Genzyme in Boston. Prior to joining Sanofi, Viehbacher spent 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the U.S. as President of GSK North America. He was a Member of the Board of Directors of GSK plc in London and Co-President of GSK's Portfolio Management Board. Viehbacher began his career with Price Waterhouse after graduating with a degree in Commerce at Queen's University in Canada.

Chris Viehbacher served as the Chairman and Chief Executive Officer of Sanofi-Aventis ADS. Viehbacher has been the Chief Executive Officer of Sanofi-Aventis S.A. (Spain) since December 1, 2008. He also serves as the Chief Executive Officer of Sanofi-Aventis S.A. France. Previously, he served as the Chief Executive Officer of Sanofi (also known as Sanofi-Aventis) from December 1, 2008 until October 2014 and served as its Managing Director. He also served as the Chief Executive Officer and President of Genzyme Corporation since April 2011.

Viehbacher served as the President of North American Pharmaceuticals for GlaxoSmithKline plc. (formerly, Wellcome GmbH) since May 2008. Later on, Viehbacher served as the President of US Pharmaceuticals Division at GlaxoSmithKline PLC from January 2003 to December 2008 and served as Member of its Corporate Executive Team. He also served as the President of Pharmaceuticals Europe of GlaxoSmithKline PLC since January 2001. He served as Co-Chairman of the Portfolio Management Board at GlaxoSmithKline PLC.

He joined Wellcome in 1988 as Chief Financial Accountant and served as its Finance Director since 1989. He served as a Director of Continental Europe at Glaxo Wellcome since 1999. He served as the President and Chief Executive Officer at Burroughs Wellcome Inc. from 1993 to 1995. Viehbacher joined Glaxo Wellcome France in 1995 and served as Vice President of Strategy and Integration, following a period based in London as a Member of the Co-ordination team during the Glaxo Wellcome integration. He served as General Manager of Glaxo Wellcome France, since 1996 and also served as its Chairman and Managing Director.

He served as a Regional Director of Europe of Glaxo Wellcome since 2000. He served with Price Waterhouse in Germany and Canada. He has been the President of the Board at European Federation of Pharmaceutical Industries and Associations since June 2013. He also serves as the Chairman of the Board at Genzyme Corporation and Genzyme Therapeutic Products Limited Partnership. He serves as the Chairman of the Board of Directors at Pharmaceutical Research and Manufacturers of America. Viehbacher served as the Chairman of Glaxo Wellcome France. He also serves as Board Member of PhRMA.

He served as the Chairman of the Board at PhRMA in the United States from December 2010 to April 2012. He served as Director of Sanofi-Aventis of Sanofi-Aventis Ireland Ltd. since December 1, 2008 until October 2014. Viehbacher served as an Executive Director of GlaxoSmithKline PLC from January 31, 2008 to September 8, 2008. Viehbacher is the Chief Executive Officer Roundtable on Cancer, North Carolina Citizens for Business and Industry and Chief Executive Officer Advisory Council, North Carolina GlaxoSmithKline Foundation and also Triangle United Way. In 2002, he was one of two industry representatives on the G10 High Level Working Group sponsored by the European Commission to restore the competitiveness of the EU Pharmaceutical Industry. In 2003, the French Republic recognized him with its prestigious Légion d'Honneur award for his contributions to business and healthcare. He completed his training as a Chartered Accountant in Canada. Viehbacher graduated from Queen's University, Ontario, with Degree in Commerce.